Mr. Fallace (Dave) is a Managing Partner and Co-Founder of Cure Ventures. He has made investments in venture capital and alternative asset funds for over 20 years. He served as a member of the investment committee of several large multibillion-dollar firms overseeing alternative investment portfolios. Across these portfolios he made investments as a limited partner and as a founding investor in start-ups.

Most recently, Dave served as an advisor for the biotech venture capital fund Polaris Partners where he evaluated Biotechnology and Health Care Information Technologies investments. During this period, he also served as an Expert-in-Resident program at Harvard University’s Office of Technology Development. Prior to Polaris, he served as a Managing Director and member of the investment committee heading the $2.5 billion diversifying strategies at TIFF Investment Management.

From 2013 to 2016, Dave served as the Director of Investments leading the $10 billion Special Opportunities program at the Alaska Permanent Fund Corporation. He spearheaded their direct venture investing serving as a board observer at Juno Therapeutics (Acquired by Celgene), and Denali Therapeutics (NASDAQ: DNLI).

Starting in 2000, Dave worked at GF Private Equity Group managing private equity and hedge fund portfolios in addition to investing in direct venture capital transactions. He served on the board or board observer of Ahura (Acquired Thermo Fisher), Alfalight (Acquired Gooch & Housego), Kotura (Acquired Mellanox), Pathscale (Acquired QLogic), Teros (Acquired Citrix), and Impinj (NASDAQ:PI).

Dave received his B.A. from Stony Brook University and his M.B.A. and J.D. from the State University of New York at Buffalo focusing on tax and financial structuring and is a member of the New York Bar.

Dr. Tartaglia (Lou) is a Managing Partner and Co-Founder of Cure Ventures. Lou’s career spans more than 30 years demonstrating scientific and therapeutic product project leadership within the biotech industry as well as investment leadership within multiple venture capital firms. His experience and skills as a rigorous scientist have manifested itself across a wide array of functional areas, allowing him to serve with distinction within the C-Suite in numerous biotech start-ups.

In 2016 Lou served as Head of 4:59, 5AM Venture’s internal de novo new company formation initiative. In that first year he led the formation of Entrada Therapeutics (NASDAQ: TRDA) and then served as interim CEO for its first year. Lou subsequently transitioned into a 5AM Venture Partner role where he has taken CEO roles at start-ups.

From 2007 to 2014 Lou served as a Partner at Third Rock Ventures where he played an integral role in the overall scientific diligence, formation, and development of its portfolio companies. While a Partner at Third Rock he played crucial roles in starting many of Third Rock’s most successful portfolio companies including as Chief Scientific Officer of Editas (NASDAQ: EDIT), Rhythm (NASDAQ: RYTM) and Agios (NASDAQ: AGIO) for the first year of operations. Beyond Third Rock he also served as Chief Executive Officer of Solstice Biologics and General Manager at GeneLogic.

Lou was formerly the first employee of and Vice President at the start-up Millennium Pharmaceuticals where he was responsible for the discovery and development of multiple therapeutic programs, which was later acquired for $8.7 Billion by Takeda Pharmaceuticals.

Lou completed his postdoctoral work at Genentech in the laboratory of Dr. David Goeddel. He received his Ph.D. in Biochemistry at the University of California, Berkeley in the laboratory of Dr. Bruce Ames and his B.S. in Chemistry at the State University of New York at Albany.

Dr. Cicmil (Milenko) has over 20 years of experience in drug discovery and development, leading multi-disciplinary scientific/project teams, portfolio strategy, and business development. His deep understanding of biology, especially in inflammation/autoimmunity and oncology matched with his drug development experience across small molecules, biologics and peptides enables him to find creative solutions for challenges faced by early-stage biotechnology startups. He spent much of his career in R&D positions of increasing responsibility within companies such as Ipsen, Fog Pharma, Merck & Co., AstraZeneca, and GE Healthcare contributing to development of multiple drugs such as: Brilinta, Symbicort, and Keytruda.

Milenko is Co-founder of Tasca Therapeutics Corp., one of the Cure Ventures portfolio companies where he currently serves as the CEO and Board member. Most recently Milenko was Vice President and Head of Global External Innovation at Ipsen, responsible for developing and leading effort generating a high-value pipeline. Prior to joining Ipsen, Milenko was Vice President, Biology at Fog Pharma, where he was responsible for scientific, strategic, and operational leadership of the Biology Department as well as contributing efforts towards the company’s financing. During his career at Merck & Co., in addition to his R&D role Milenko also served as a Director at Merck’s Innovation Hub where he led search & evaluation efforts for in-licensing/partnership opportunities in Immuno-Oncology, Immunology and Ophthalmology. Milenko’s early R&D career at AstraZeneca spanned a variety of roles including managing teams of scientists and projects within immunology and inflammation therapy areas delivering over 20 clinical development candidate drugs.

Milenko is currently a Visiting Research Fellow at University of Reading, UK where he completed a Ph.D. in Molecular Pharmacology. Milenko received BSc in Molecular Biology from Kings College, London, UK. Prior to joining the pharmaceutical industry, Milenko was a postdoctoral fellow at the Cancer Research UK.